• Send Us A Tip
  • Calling all Tech Writers
  • Advertise
Saturday, May 17, 2025
  • Login
  • Register
TechStory
  • News
  • Crypto
  • Gadgets
  • Memes
  • Gaming
  • Cars
  • AI
  • Startups
  • Markets
  • How to
No Result
View All Result
  • News
  • Crypto
  • Gadgets
  • Memes
  • Gaming
  • Cars
  • AI
  • Startups
  • Markets
  • How to
No Result
View All Result
TechStory
No Result
View All Result
Home Business

Acceleron Pharma Stock rises 7% after a $11bn deal with Merck

by Rohit Yadav
September 28, 2021
in Business, Markets, News, Trending
Reading Time: 2 mins read
0
Acceleron Stock

Image: Wall Street Journal

TwitterWhatsappLinkedin

On Monday, rumors surfaced that Acceleron Pharma (XLRN) was in discussions to be bought by a big pharmaceutical firm for around $11 billion.

You might also like

Global AI Race: UAE Invests Big in New Campus, with Trump’s Endorsement

Turkey’s Celebi Takes Legal Aim at India Over Security Clearance Cancellation Amid Pakistan Tensions

TikTok Faces EU Charges Over Breach of Content Transparency Laws

Acceleron Stock
Image: Wall Street Journal

At the time of writing, the Cambridge, Massachusetts-based firm’s stock was up nearly 6.7% to $178.87.

What’s the matter?

The identity of the potential buyer was not revealed, but Bloomberg reported that several global drugmakers are interested, including Bristol-Myers Squibb (BMY), which owns 11.5 percent of Acceleron’s stock.

According to Wall Street Journal sources familiar with the issue, Merck MRK & Co. is in advanced discussions to buy Acceleron Pharma Inc., XLRN, in a move that would strengthen the pharmaceutical giant’s rare disease business.
Merck appears to have outbid other possible Acceleron bidders, including Bristol Myers Squibb Co., which already holds a significant interest in the firm.

Bloomberg reported that the deal will cost around $180 per share in cash, citing individuals familiar with the situation. A request for comment from Acceleron was not immediately returned.

According to the Fly, the study prompted RBC Capital analyst Kennen MacKay to boost his price objective for Acceleron to $179 from $113, while maintaining a sector-perform rating on the stock.

Given the history of consolidation in the pulmonary arterial hypertension discipline, MacKay believes M&A interest is probable. The unique mode of action of Acceleron’s sotatercept has the potential to complement the portfolio of current competitors in the sector, he added.

Acceleron focuses on discovering, developing, and commercializing medicines to treat severe and rare diseases, with a market value of $10.2 billion and around 370 employees. The firm produces Reblozyl, which is used to treat anemia in people with beta-thalassemia and transfusion-dependent anemia.

Acceleron posted a larger-than-expected second-quarter loss of $1.05 per share in August, up from 34 cents a year earlier and missing the Zacks consensus of 92 cents per share. Reblozyl net sales generated $27.9 million in revenue, which included $2.3 million in cost-share revenue and $25.6 million in royalty revenue. The company’s income was entirely derived from its agreement with Bristol-Myers Squibb.

Acceleron to agree on the deal

Acceleron has yet to agree to a takeover by any possible suitor, according to Bloomberg. That’s essential to remember that $11 billion for a firm with a promising PAH treatment appears to be a lowball offer that shareholders are unlikely to accept, especially given the company already has a market valuation of $10.2 billion. After all, it was only four years ago that Johnson & Johnson paid $30 billion for the Swiss biotech company Actelion and its PAH pipeline.

What happens next?

Now, if the proper type of acquisition doesn’t occur, Acceleron might simply choose to remain a stand-alone firm. Alternatively, management may choose to adopt a risk-free strategy and accept a contract before Sotatercept’s clinical programme is completed. In any case, biotech investors will want to keep a watch on this company in the coming weeks. After all, buyouts are known to send shockwaves across the biotech sector.

Tags: Acceleron PharmaMerckpharmaceuticalStock
Tweet54SendShare15
Previous Post

ICICI Bank partners with Amazon India to offer OD facility to sellers and small businesses

Next Post

You shouldn’t buy Thoughtworks Stock now, Here’s why!

Rohit Yadav

Hi! I'm Rohit, If you like reading about markets, technology and business, you've come to the right place. Catch me: [email protected]

Recommended For You

Global AI Race: UAE Invests Big in New Campus, with Trump’s Endorsement

by Sneha Singh
May 17, 2025
0
Global AI Race: UAE Invests Big in New Campus, with Trump's Endorsement

UAE will construct the largest artificial intelligence campus outside of the US following the sealing of a historic deal during Donald Trump's recent Middle East visit. The Abu...

Read more

Turkey’s Celebi Takes Legal Aim at India Over Security Clearance Cancellation Amid Pakistan Tensions

by Anochie Esther
May 17, 2025
0
Çelebi Aviation

In a rapidly escalating diplomatic and corporate standoff, Turkish aviation services company Çelebi Aviation has filed a legal challenge against the Indian government’s decision to revoke its security...

Read more

TikTok Faces EU Charges Over Breach of Content Transparency Laws

by Anochie Esther
May 17, 2025
0
Tiktok

TikTok, one of the world’s most popular social media platforms, is under intense scrutiny in Europe after being formally charged by EU regulators with breaching key online content...

Read more
Next Post
Thoughtworks

You shouldn't buy Thoughtworks Stock now, Here's why!

Please login to join discussion

Techstory

Tech and Business News from around the world. Follow along for latest in the world of Tech, AI, Crypto, EVs, Business Personalities and more.
reach us at [email protected]

Advertise With Us

Reach out at - [email protected]

BROWSE BY TAG

#Crypto #howto 2024 acquisition AI amazon Apple bitcoin Business China cryptocurrency e-commerce electric vehicles Elon Musk Ethereum facebook flipkart funding Gaming Google India Instagram Investment ios iPhone IPO Market Markets Meta Microsoft News NFT samsung Social Media SpaceX startup startups tech technology Tesla TikTok trend trending twitter US

© 2024 Techstory.in

No Result
View All Result
  • News
  • Crypto
  • Gadgets
  • Memes
  • Gaming
  • Cars
  • AI
  • Startups
  • Markets
  • How to

© 2024 Techstory.in

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?